Early real-world experience with thoracoabdominal branch endoprosthesis from a physician-initiated multicenter postmarket registry
Journal of Vascular Surgery · 2026-12 · 84 (6) · 1347-1355.e1
DOI: 10.1016/j.jvs.2026.06.161 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Vascular Surgery, 2026-12. Verfasst von Carrie Tackett und 11 weiteren Autor:innen. Beteiligte Einrichtung: Comprehensive Aortic Center, Keck Medical Center of University of Southern California, Los Angeles, CA. Hauptthemen laut MEDLINE: Blood Vessel Prosthesis, Endovascular Aneurysm Repair, Aortic Aneurysm, Thoracic, Stents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: Recent commercial approval of the thoracoabdominal multibranch endoprosthesis (TAMBE) has enabled wide dissemination of four-vessel multibranched endovascular aortic repairs in the United States. However, the real-world performance benchmarks remain incompletely characterized. This study evaluated 30-day clinical outcomes of patients receiving TAMBE across diverse practice settings. METHODS: We performed a retrospective study of commercial TAMBE implants across multiple US centers between May 2024 and November 2025. The primary outcomes were 30-day mortality and technical success. Secondary outcomes included overall adverse events (AE) and major adverse events (MAE). Intraoperative metrics and clinical outcomes were compared between centers with previous investigational access to TAMBE (PRE) and those adopting the device after commercial approval (POST). RESULTS: A total of 182 patients from 11 centers were included. The mean age was 73.8 ± 9.01 years. Most patients were the American Society of Anesthesiologists class III (51.6%) or IV (36.3%), with a high prevalence of previous aortic repairs (20.1% open; 40.5% endovascular repair). Aneurysm extent included complex abdominal aneurysms (68.3%) and thoracoabdominal aneurysms (31.7%). Technical success was achieved in 95% of cases. Thirty-day mortality was 3.3%, and 20.3% of patients experienced AE, among which MAE occurred in 13.7%. Technical success, 30-day mortality, and MAE did not differ between the PRE and POST centers. POST centers had longer operative, fluoroscopy times, and higher 30-day AE (33.3% vs 11.8%, P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Comprehensive Aortic Center, Keck Medical Center of University of Southern California, Los Angeles, CA.
- Department of Vascular & Endovascular Surgery, Kaiser Permanente, San Diego, CA.
- Department of Vascular Surgery, University of Missouri, Columbia, MO.
- Department of Vascular Surgery, Stanford, Palo Alto, CA.
- Department of Vascular Surgery, University of Texas Southwestern, Dallas, TX.
- Division of Vascular Surgery, University of North Carolina, Chapel Hill, NC.
Zitieren
APA
Tackett, C., Parsa, P., Bath, J., Lee, J. T., Timaran, C., Farber, M. A., Mendes, B., Yoon, W., Khoury, M. K., Droz, N., Rana, A., & Han, S. M. (2026). Early real-world experience with thoracoabdominal branch endoprosthesis from a physician-initiated multicenter postmarket registry. Journal of Vascular Surgery, 84(6), 1347-1355.e1. https://doi.org/10.1016/j.jvs.2026.06.161
Vancouver
Tackett C, Parsa P, Bath J, Lee JT, Timaran C, Farber MA, et al. Early real-world experience with thoracoabdominal branch endoprosthesis from a physician-initiated multicenter postmarket registry. Journal of Vascular Surgery. 2026;84(6):1347-1355.e1. doi:10.1016/j.jvs.2026.06.161
BibTeX
@article{Tackett2026,
author = {Tackett, Carrie and Parsa, Pouria and Bath, Jonathan and Lee, Jason T and Timaran, Carlos and Farber, Mark A and Mendes, Bernardo and Yoon, William and Khoury, Mitri K and Droz, Nathan and Rana, Ali and Han, Sukgu M},
title = {Early real-world experience with thoracoabdominal branch endoprosthesis from a physician-initiated multicenter postmarket registry},
journal = {Journal of Vascular Surgery},
year = {2026},
volume = {84},
number = {6},
pages = {1347--1355.e1},
doi = {10.1016/j.jvs.2026.06.161}
}
EUVIMED